Latest news with #EliLilly&Co.
Bloomberg
01-05-2025
- Business
- Bloomberg
Obesity Drug Price Wars Heating Up as CVS Picks Novo Over Lilly
The obesity drug price wars are finally starting. After being publicly lambasted for the high cost of their weight-loss shots, two of world's biggest drugmakers — Eli Lilly & Co. and Novo Nordisk A/S — are racing to lock up deals with drug benefit managers that control which prescriptions many Americans get as well as popular telehealth companies that sell directly to consumers. Investors are worried about how low prices will go.
Bloomberg
01-05-2025
- Business
- Bloomberg
Q&A: What Trump's First 100 Days Tell Us About America's Future
On this episode of Stock Movers: - Kohl's (KSS) shares rise after the company fired its chief executive officer after the board found he directed the company to do millions of dollars of business with someone he had a personal relationship with on 'highly unusual terms.' The company said it is starting a search to find a permanent replacement following the departure of Ashley Buchanan and that Chairman Michael Bender would serve as interim CEO, according to a statement. - Eli Lilly & Co.'s (LLY) shares dropped in morning trading after CVS Health Corp. announced a plan to drop its blockbuster weight-loss drug Zepbound, making rival Wegovy more widely available. The drugmaker also cut its full-year earnings outlook, citing research and development costs. - Microsoft (MSFT) shares surge after the company reported stronger-than-expected quarterly sales and profit growth, suggesting customer demand for cloud services has held steady despite a wave of tariffs and economic turbulence. During a call with analysts, Chief Financial Officer Amy Hood said Azure will grow as much as 35%.
Bloomberg
01-05-2025
- Business
- Bloomberg
Stock Movers: Meta, Eli Lilly, Kohl's
On this episode of Stock Movers: - Meta Platforms (META) shares jumped after the company's advertising sales quelled Wall Street concerns about the impact of the Trump administration's trade war, with first-quarter revenue beating expectations. Meta needs its advertising business, which makes up 98% of the company's revenue, to continue growing in order to fund an expensive expansion in artificial intelligence. - Eli Lilly & Co.'s (LLY) shares dropped in morning trading after CVS Health Corp. announced a plan to drop its blockbuster weight-loss drug Zepbound, making rival Wegovy more widely available. The drugmaker also cut its full-year earnings outlook, citing research and development costs. - Kohl's (KSS) shares rise after the company fired its chief executive officer after the board found he directed the company to do millions of dollars of business with someone he had a personal relationship with on 'highly unusual terms.' The company said it is starting a search to find a permanent replacement following the departure of Ashley Buchanan and that Chairman Michael Bender would serve as interim CEO, according to a statement.
Bloomberg
23-04-2025
- Business
- Bloomberg
Zealand Pharma Hires Lilly Executive as Biotech Ramps Up in Obesity
Zealand Pharma A/S hired a senior executive from Eli Lilly & Co. after an agreement with a major drugmaker helped bolster its ambitions in obesity. The Danish biotech named Utpal Singh as its chief scientific officer on Wednesday. Singh just relocated from the US after spending more than 18 years at Lilly, most recently as senior vice president of small molecule discovery.
Bloomberg
22-04-2025
- Business
- Bloomberg
Novo Nordisk Slides on Pressure From Lilly's Pill Study
Novo Nordisk A/S slumped after a pill from rival Eli Lilly & Co. helped patients shed weight and control blood sugar about as well as its injected blockbuster Ozempic. The stock dropped as much as 9.8% to 380 kroner early in Copenhagen, the first trading day since the Thursday announcement that buoyed Lilly.
